Advanced search
1 file | 1.79 MB Add to list

A review of the ADAMTS family, pharmaceutical targets of the future

(2009) CURRENT PHARMACEUTICAL DESIGN. 15(20). p.2359-2374
Author
Organization
Abstract
The a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family of metalloproteases consists of 19 members. These enzymes play an important role in the turnover of extracellular matrix proteins in various tissues and their altered regulation has been implicated in diseases such as cancer, arthritis and atherosclerosis. Unlike other metalloproteinases, ADAMTS members demonstrate a narrow substrate specificity due to the various exosites located in the C-terminal regions of the enzymes, which influence protein recognition and matrix localization. The tight substrate specificity exhibited by ADAMTS enzymes makes them potentially safe pharmaceutical targets, as selective inhibitors designed for each member will result in the inhibition or cleavage of only a limited number of proteins. With the recent elucidation of crystal structures for ADAMTS-1, -4 and -5, the design of potent and selective small molecule inhibitors is underway and will lead to drug candidates for evaluation in clinical trials in the next 5-10 years.
Keywords
metalloproteinase, aggrecanase, ADAMTS, EHLERS-DANLOS-SYNDROME, VON-WILLEBRAND-FACTOR, THROMBOTIC THROMBOCYTOPENIC PURPURA, WEILL-MARCHESANI-SYNDROME, BONE MORPHOGENETIC PROTEIN-1, FACTOR-CLEAVING PROTEASE, OLIGOMERIC MATRIX PROTEIN, HUMAN ARTICULAR-CARTILAGE, PROCOLLAGEN N-PROTEINASE, HUMAN BREAST-CARCINOMA

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.79 MB

Citation

Please use this url to cite or link to this publication:

MLA
Tortorella, Micky D, Fransiska Malfait, Ruteja A Barve, et al. “A Review of the ADAMTS Family, Pharmaceutical Targets of the Future.” CURRENT PHARMACEUTICAL DESIGN 15.20 (2009): 2359–2374. Print.
APA
Tortorella, M. D., Malfait, F., Barve, R. A., Shieh, H.-S., & Malfait, A.-M. (2009). A review of the ADAMTS family, pharmaceutical targets of the future. CURRENT PHARMACEUTICAL DESIGN, 15(20), 2359–2374.
Chicago author-date
Tortorella, Micky D, Fransiska Malfait, Ruteja A Barve, Huey-Sheng Shieh, and Anne-Marie Malfait. 2009. “A Review of the ADAMTS Family, Pharmaceutical Targets of the Future.” Current Pharmaceutical Design 15 (20): 2359–2374.
Chicago author-date (all authors)
Tortorella, Micky D, Fransiska Malfait, Ruteja A Barve, Huey-Sheng Shieh, and Anne-Marie Malfait. 2009. “A Review of the ADAMTS Family, Pharmaceutical Targets of the Future.” Current Pharmaceutical Design 15 (20): 2359–2374.
Vancouver
1.
Tortorella MD, Malfait F, Barve RA, Shieh H-S, Malfait A-M. A review of the ADAMTS family, pharmaceutical targets of the future. CURRENT PHARMACEUTICAL DESIGN. 2009;15(20):2359–74.
IEEE
[1]
M. D. Tortorella, F. Malfait, R. A. Barve, H.-S. Shieh, and A.-M. Malfait, “A review of the ADAMTS family, pharmaceutical targets of the future,” CURRENT PHARMACEUTICAL DESIGN, vol. 15, no. 20, pp. 2359–2374, 2009.
@article{4252029,
  abstract     = {The a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family of metalloproteases consists of 19 members. These enzymes play an important role in the turnover of extracellular matrix proteins in various tissues and their altered regulation has been implicated in diseases such as cancer, arthritis and atherosclerosis. Unlike other metalloproteinases, ADAMTS members demonstrate a narrow substrate specificity due to the various exosites located in the C-terminal regions of the enzymes, which influence protein recognition and matrix localization. The tight substrate specificity exhibited by ADAMTS enzymes makes them potentially safe pharmaceutical targets, as selective inhibitors designed for each member will result in the inhibition or cleavage of only a limited number of proteins. With the recent elucidation of crystal structures for ADAMTS-1, -4 and -5, the design of potent and selective small molecule inhibitors is underway and will lead to drug candidates for evaluation in clinical trials in the next 5-10 years.},
  author       = {Tortorella, Micky D and Malfait, Fransiska and Barve, Ruteja A and Shieh, Huey-Sheng and Malfait, Anne-Marie},
  issn         = {1381-6128},
  journal      = {CURRENT PHARMACEUTICAL DESIGN},
  keywords     = {metalloproteinase,aggrecanase,ADAMTS,EHLERS-DANLOS-SYNDROME,VON-WILLEBRAND-FACTOR,THROMBOTIC THROMBOCYTOPENIC PURPURA,WEILL-MARCHESANI-SYNDROME,BONE MORPHOGENETIC PROTEIN-1,FACTOR-CLEAVING PROTEASE,OLIGOMERIC MATRIX PROTEIN,HUMAN ARTICULAR-CARTILAGE,PROCOLLAGEN N-PROTEINASE,HUMAN BREAST-CARCINOMA},
  language     = {eng},
  number       = {20},
  pages        = {2359--2374},
  title        = {A review of the ADAMTS family, pharmaceutical targets of the future},
  volume       = {15},
  year         = {2009},
}

Web of Science
Times cited: